Bhavik Patel Sells 1,855 Shares of IQVIA (NYSE:IQV) Stock

IQVIA Holdings Inc. (NYSE:IQV) insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This represents a 57.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

IQVIA Trading Down 2.2%

IQV stock traded down $5.18 during trading on Tuesday, reaching $228.18. 1,471,738 shares of the stock were exchanged, compared to its average volume of 1,812,230. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a 50 day moving average price of $196.05 and a 200-day moving average price of $186.76. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $251.36. The firm has a market capitalization of $37.56 billion, a price-to-earnings ratio of 28.31, a P/E/G ratio of 1.99 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 11.61 earnings per share for the current year.

IQVIA declared that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA during the 4th quarter worth approximately $25,000. Financial Freedom LLC purchased a new position in IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors acquired a new position in shares of IQVIA in the first quarter worth $25,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth $27,000. Finally, Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research report on Thursday, July 9th. Royal Bank Of Canada lifted their price target on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Robert W. Baird upped their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.